Gentlemen, CHECKvacc is CF33 combined with an anti-PD-L1, and the trial is independent of MAST. The main similarity is that CF33 is the intended cytotoxic backbone, which highlights that it is not an active compound in cancer.
The initial study design published on clinical trials October 2021 states the estimated enrollment for the CHECKvacc trial was 78 patients.
By June 2022, they had 6 patients treated. Five of the six patients progressed, while one achieved a stable disease.
This information can only be found via the San Antonio Breast Cancer Symposium (SABC) 2022 located on IMUs website and published December 2022. Perhaps you can see for yourself the information that was withheld from the price sensitive announcement updating IMU shareholders.
https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/6392686e3b79462db75f4edb/1670539377946/21094+SABCS+2022+11-11-22.pdf
The efficacy from the phase 1 trial was released to market hidden away in an symposium presentation, but this did not preven Imugene MD & CEO Leslie Chong from saying:
The fourth cohort, however, was never dosed. Enrollment update from January 2024 indicates that only 9 patients have been enrolled and no further updates have been made as the trial is active and not recruiting. The last update that can be found by holders is the July 2023 CHECKvacc update indicating that 8 patients had been treated and there were no responses. IMU management have not posted the poster to the website, which indicates to me 0 responses from 8 patients.
Despite progressing through 3 dose escalations, IMU shareholders were never formally updated on the patients outcomes. Each investor can determine for themselves whether this was done in conjunction with a positive outlook on trial progress.
(20min delay)